Skip to content

Comparing different techniques that may help epilepsy patients take their medicines

Compliance to drug therapy of Epilepsy patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
REBEC
Registry ID
RBR-943kwq
Enrollment
Unknown
Registered
2014-06-26
Start date
2013-02-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Control Group or Conventional Care Group: 30 epilepsy patients in ambulatory care that received individual orientation about the use of anti-epileptic drugs prescribed on medical consultation and elab
on the day the intervention was applied (first contact with the patient), six weeks after the intervention and six months after first contact. Blood levels of anti-epileptic drugs were also collected
Behavioural

Sponsors

Escola de Enfermagem da Universidade de São Paulo
Lead Sponsor
Cristina Helena Costanti Settervall
Collaborator

Eligibility

Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients, from both genders, aged between 18 and 100 years-old, diagnosed with epilepsy in ambulatory care for over one year, with at least four years of school, independent in daily life activities, without mental and psychic disabilities, presenting medium, or low adherence by the Morisky test.

Exclusion criteria

Exclusion criteria: Patients with medical prescription with weekly or daily increase or removal of anti-epileptic drugs, including Carbamazepine, phenytoin, phenobarbital and valproate sodium; those that already use the resources tested in this trial to enhance compliance and with other chronic diseases in continuous drug treatment.

Design outcomes

Primary

MeasureTime frame
Achieve after one month of the application of the interventions increase or maintenance in therapeutic values anti-epileptic drugs blood levels; reduction of the number of epileptic crises, reported by the patient; enhance compliance by the evaluation of the Morisky test.

Secondary

MeasureTime frame
Stability of the positive effects after six months of application of the interventions (increase or maintenance in therapeutic values anti-epileptic drugs blood levels; reduction of the number of epileptic crises, reported by the patient; enhance compliance by the evaluation of the Morisky test).

Countries

Brazil

Contacts

Public ContactCristina;Regina Costanti Settervall;Cardoso de Sousa

Escola de Enfermagem da Universidade de São Paulo;Escola de Enfermagem da Universidade de São Paulo

cristina.settervall@gmail.com;vian@usp.br+55 (11) 98118- 3186;+55 (11) 3061-7563

Outcome results

None listed

Source: REBEC (via WHO ICTRP)